,
Pazan, Farhad
Weiss, Christel
Wehling, Martin
Article History
First Online: 15 January 2018
Change Date: 2 July 2018
Change Type: Correction
Change Details: In the original publication of this article, the members of the FORTA group were provided in such a way that they could not be indexed as collaborators on PubMed. The article should have included an Acknowledgement section as shown below.
Compliance with ethical standards
:
: No sources of funding were received for this project or for the preparation of this manuscript.
: M.W. was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (=translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Boehringer-Ingelheim, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Berlin-Chemie, Shire and LEO Pharma. F.P. and C.W. have no conflicts of interest to declare.